VSL#3 is a high-potency probiotic mixture containing eight different strains of live bacteria, classified as a “medical food” rather than a standard dietary supplement. It’s one of the most studied probiotic formulations in the world, with the bulk of its clinical evidence centered on inflammatory bowel conditions like ulcerative colitis and pouchitis.
How VSL#3 Differs From Regular Probiotics
Most over-the-counter probiotics contain one to three bacterial strains and deliver somewhere between 1 billion and 20 billion colony-forming units per dose. VSL#3 operates on a different scale entirely, packing eight distinct strains into a single formulation at concentrations that dwarf typical supplements. That potency is part of why the FDA categorizes it as a medical food, a designation that places it in a middle ground between a conventional supplement and a prescription drug.
Under FDA rules, a medical food must be specially formulated for a specific disease or condition, intended for patients whose nutritional needs can’t be met through diet alone, and used under the supervision of a physician. VSL#3 meets all of those criteria. You won’t find it shelved alongside multivitamins. It’s meant to be part of an active treatment plan, typically for a diagnosed digestive condition.
What It’s Used For
The strongest evidence for VSL#3 involves ulcerative colitis, a form of inflammatory bowel disease where the lining of the colon becomes chronically inflamed. A meta-analysis of clinical trials found that 43.8% of patients taking VSL#3 achieved remission, compared to 24.8% of those given a placebo. The response rate (meaning meaningful symptom improvement, even if not full remission) was 53.4% for VSL#3 versus 29.3% for placebo. In practical terms, for every three to five patients treated with VSL#3 alongside standard therapy, one additional patient improved who otherwise would not have.
Beyond ulcerative colitis, VSL#3 has been studied across a wide range of conditions:
- Pouchitis: inflammation of the surgically created pouch after colon removal, one of the earliest and best-supported uses
- Irritable bowel syndrome (IBS): particularly diarrhea-predominant forms
- Antibiotic-associated diarrhea: disruption of gut bacteria from antibiotic courses
- Chemotherapy-induced diarrhea
- Liver conditions: including non-alcoholic fatty liver disease and hepatic encephalopathy, a complication of advanced liver disease
The depth of evidence varies. Ulcerative colitis and pouchitis have the most robust trial data, while conditions like liver disease and chronic prostatitis have more preliminary support.
How It Works in the Gut
The core problem in conditions like ulcerative colitis is a breakdown of the intestinal barrier. Your gut lining is held together by proteins that form tight junctions between cells, acting like seals that control what passes through. When the gut is inflamed, signaling molecules (particularly one called interferon-gamma) strip away those seal proteins and make the lining porous. That increased permeability lets bacteria and other irritants slip through, fueling more inflammation in a self-reinforcing cycle.
VSL#3 interrupts this cycle by boosting the activity of a natural enzyme in gut cells that dials down inflammatory signaling. Lab studies show it restores the seal proteins to their normal positions and levels, essentially patching the leaky barrier. In cell models, VSL#3 reversed the permeability damage caused by inflammation in a dose-dependent way, meaning higher concentrations produced stronger repair. Importantly, when the enzyme VSL#3 relies on was deliberately disabled in lab cells, the probiotic lost its protective effect, confirming the mechanism rather than leaving it to speculation.
The VSL#3 vs. Visbiome Confusion
If you’ve researched VSL#3 online, you’ve likely encountered confusing references to Visbiome, Vivomixx, or something called the “De Simone Formulation.” This traces back to a legal and manufacturing split that happened around 2016.
The original VSL#3 formulation was developed by Professor Claudio De Simone and manufactured at a Danisco/DuPont facility in the United States. After a business dispute, the VSL#3 brand name was transferred to a different manufacturer (CSL/Nutrilinea in Italy), while the original formulation continued under new brand names: Visbiome in the U.S., Vivomixx in Europe, and DeSimone Formulation in Korea.
This matters because the clinical trials that built VSL#3’s reputation were conducted with the original formulation. Research published in Frontiers in Immunology noted that the product now sold as VSL#3 is “a different probiotic mix” from the one used in those landmark studies. If you’re trying to match the formulation that was actually tested in clinical trials, the product now called Visbiome (in the U.S.) is the one with continuity to that research. The current VSL#3 product may or may not perform identically; it simply hasn’t been through the same body of trials.
What to Expect When Taking It
VSL#3 comes in sachets (powder packets you mix into a cold drink or soft food) and capsules. The sachets deliver a higher bacterial count per dose than the capsules, and clinical trials for ulcerative colitis typically used the higher-dose sachet form. The product needs refrigeration to keep the bacteria alive, which is another difference from shelf-stable probiotics you might be used to.
The most commonly reported side effect is temporary bloating or gas, particularly during the first few days as your gut adjusts to the influx of bacteria. This tends to settle within a week. Because the formulation contains lactobacillus and bifidobacterium species, people with severe immune suppression should be cautious. Live bacterial supplements carry a small but real risk of causing infection in people whose immune systems can’t keep the bacteria confined to the gut.
Results aren’t instant. In clinical trials for ulcerative colitis, patients were typically assessed after 8 to 12 weeks of daily use. If you’re using it for a chronic condition, give it at least a couple of months before drawing conclusions about whether it’s working.